Repository logo
 
Publication

De novo human angiotensin - converting enzyme 2 Decoy NL-CVX1 protects mice from severe disease after severe acute respiratory syndrome coronavirus 2 infection

2023-09-15Journal article Open access
Simple item page
dc.contributor.authorRebelo, Maria
dc.contributor.authorTang, Cong
dc.contributor.authorCoelho, Ana R.
dc.contributor.authorLabão-Almeida, Carlos
dc.contributor.authorSchneider, Matthias M.
dc.contributor.authorTatalick, Laurie
dc.contributor.authorRuivo, Pedro
dc.contributor.authorde Miranda, Marta Pires
dc.contributor.authorGomes, Andreia
dc.contributor.authorCarvalho, Tânia
dc.contributor.authorWalker, Matthew J.
dc.contributor.authorAusserwoeger, Hannes
dc.contributor.authorSimas, J. Pedro
dc.contributor.authorVeldhoen, Marc
dc.contributor.authorKnowles, Tuomas P. J.
dc.contributor.authorSilva, Daniel Adriano
dc.contributor.authorShoultz, David
dc.contributor.authorBernardes, Gonçalo J. L.
dc.date.accessioned2023-10-04T15:40:51Z
dc.date.available2023-10-04T15:40:51Z
dc.date.issued2023-09-15
dc.description.abstractThe emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.eid85171601438
dc.identifier.issn0022-1899
dc.identifier.pmcPMC10503951
dc.identifier.pmid37279654
dc.identifier.urihttp://hdl.handle.net/10400.14/42778
dc.identifier.wos001002059700001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectDe novo protein decoyspt_PT
dc.subjectK18-hACE2 micept_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectTreatmentpt_PT
dc.titleDe novo human angiotensin - converting enzyme 2 Decoy NL-CVX1 protects mice from severe disease after severe acute respiratory syndrome coronavirus 2 infectionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage733pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage723pt_PT
oaire.citation.titleThe Journal of infectious diseasespt_PT
oaire.citation.volume228pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
75478747.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CBR - Contribuições em Revistas Científicas / Contribution to Journals